US Patent protects the RITM SCENAR IP



The newest RITM SCENAR technology incorporating biocontrolled feedback (bioF, bioInt and bioGap) is now patented in the United States!

The patent application No. 15778519 “METHOD OF ADAPTIVE ELECTRIC ACTION ON A LIVING ORGANISM (VARIANTS)” (authors Y.Z. Grinberg, Y.Y. Starovoytov, M.A. Unakafov) has received a positive decision!
This ensures the protection of the Russian patent No.2645923 from December 1st, 2015, in the United States.

GSU

The latest development in SCENAR – BioFrequency, bioGap and bioIntensity, incorporated in the 2018 SCENAR models – are now protected with an US patent.

These fully automatic functions provide real time interaction between the device and the user. The Frequency, Gap and Intensity change according to the body’s reaction which is a whole new level of electrical stimulation.

The Bio-adaptive modes are significantly more effective for chronic and acute pain.



October 15, 2019

0 responses on "US Patent protects the RITM SCENAR IP"

Leave a Message

RITM Australia Pty Ltd